SCHEDULE: RA Capital Discloses 6.9% Stake in Lexeo Therapeutics

RA Capital Management and its affiliates have reported a 6.9% beneficial ownership stake in Lexeo Therapeutics, Inc., totaling 5,000,000 shares.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed a Schedule 13G regarding Lexeo Therapeutics, Inc.
• The Reporting Persons beneficially own 5,000,000 shares of Lexeo Therapeutics, Inc. common stock.
• This ownership represents 6.9% of Lexeo Therapeutics' outstanding common stock.
• The shares are held with shared voting and shared dispositive power among the Reporting Persons.
• The percentage is calculated based on 54,001,214 shares outstanding as of August 12, 2025, plus 17,968,750 shares issued in a public offering that closed on October 20, 2025.
• The acquisition was not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 8

Explanation: The disclosure of a significant stake by a reputable healthcare-focused institutional investor like RA Capital Management is a strong positive signal, indicating confidence in Lexeo Therapeutics. This type of investment often precedes positive market sentiment and potential future growth, despite the passive nature of the 13G filing.

Positives

• A significant institutional investor, RA Capital Management, has taken a substantial 6.9% stake in Lexeo Therapeutics, indicating confidence in the company's prospects.
• The investment by a specialized healthcare fund (RA Capital Healthcare Fund, L.P.) suggests a strategic interest in Lexeo's sector and potential for future growth.

Risks

• The filing itself does not detail company-specific risks for Lexeo Therapeutics, Inc.
• The Reporting Persons disclaim beneficial ownership for purposes other than Section 13(d) obligations, which could imply a passive investment stance and limited direct engagement in company operations.

Future Outlook

The filing is a Schedule 13G and does not contain any forward-looking statements or guidance regarding Lexeo Therapeutics, Inc.'s future performance or strategic direction.

Management Comments

• The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G.
• The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's portfolio, including the shares of the Issuer's common stock reported herein.
• Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act.
• RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.
• I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing indicates continued institutional investor interest in the biotechnology and pharmaceutical sector, specifically in companies like Lexeo Therapeutics. RA Capital Management is a prominent healthcare-focused investment firm, and their significant stake suggests a positive view on Lexeo's potential within the competitive biotech landscape, potentially signaling a trend of strategic investments in promising early to mid-stage therapeutic developers.

Stakeholder Impact

• Shareholders: Existing shareholders may see increased confidence and potentially a positive impact on share price due to a major institutional investor taking a significant stake.
• Company Management: The investment by RA Capital could provide strategic validation and potentially open doors for future collaborations or financing, although the filing disclaims intent to influence control.

Next Steps

• The filing does not explicitly mention any future actions, events, or milestones for Lexeo Therapeutics or the Reporting Persons beyond the ongoing beneficial ownership.

Key Dates

Recommendation

The disclosure of a 6.9% stake by RA Capital Management, a highly respected healthcare-focused investment firm, signals strong institutional confidence in Lexeo Therapeutics. This significant investment, especially following a recent public offering, suggests that a sophisticated investor sees substantial upside potential. While the filing itself is passive, the presence of such a prominent investor on the shareholder register often acts as a catalyst for positive market sentiment and can attract further institutional interest, making it an attractive 'buy' for investors looking for validation from industry experts.

Keywords

Lexeo Therapeutics, RA Capital Management, Schedule 13G, Institutional Investment, Biotechnology, Healthcare Fund, Equity Stake, Beneficial Ownership, LXEO